enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
-$0.02 today
- Market cap
- $123.98M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
Volume 2.81M
Average 1.58M
ENGN Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
enGene Holdings Inc.NASDAQ: ENGN
Accumulated OCI · Q2 FY2026 · quarter ended Apr 2026
Accumulated OCI remains negative
Q2 FY2026 Accumulated OCI was -$1.14M, compared with -$969K a year earlier.
Context
- Accumulated OCI amounted to 0.4% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -17.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (888K) USD
- Year-over-year change
- +37.4%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (888K) | +37.4% |
| FY2024 | 2024-10-31 | (1.42M) | -39.7% |
| FY2023 | 2023-10-31 | (1.02M) | — |
| FY2022 | 2022-10-31 | 0 | — |
| FY2021 | 2021-10-31 | 0 | — |
Accumulated OCI vs competitors
How ENGN compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -17.8% is the 7th highest of 10, against a peer median of -4.4%.
- Accumulated OCI amounts to 0.4% of total assets for ENGN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $13K USD | -7.1% | — | 0.0% | |
| Mar 2026 | CHF 7K CHF | +800.0% | -11.2% | 0.0% | |
| Mar 2026 | $6K USD | -88.9% | — | 0.0% | |
| Mar 2026 | $5K USD | -98.1% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | -$81K USD | +11.0% | — | 0.0% | |
ENGNenGene Holdings Inc. | Apr 2026 | -$1.14M USD | -17.8% | — | 0.4% |
| Mar 2026 | -$3.37M USD | -141.7% | — | 2.9% | |
| Mar 2026 | -$5.22M USD | -4.4% | — | 1.6% | |
| Mar 2026 | -$9.9M USD | +13.0% | — | 3.7% | |
| Mar 2026 | -$33.2M USD | +10.9% | — | 11.5% | |
| Peer median (excluding ENGN) | — | -4.4% | -11.2% | 0.0% | |
Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.07M | 314.15K | 81.52M | 173M | 50.15M |
| Short-term Investments | 0 | 0 | 76K | 65.4M | 143.66M |
| Net Receivables | 0 | 0 | 2.34M | 1.03M | 2.23M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 1.5M | 7.93M | 5.35M |
| Total Current Assets | 1.57M | 511.8K | 85.44M | 247.36M | 201.39M |
| Property, Plant & Equipment (Net) | 0 | 0 | 589K | 2.91M | 10.19M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 129.67M | 131.53M | 70K | 59.53M | 8.52M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 209.05K | 939K | 860K | 1.37M | 1.36M |
| Total Non-current Assets | 129.88M | 131.53M | 1.52M | 63.81M | 20.08M |
| Total Assets | 131.45M | 132.04M | 86.96M | 311.17M | 221.47M |
| Account Payables | 0 | 0 | 1.16M | 1.41M | 6.69M |
| Short-term Debt | 1.05M | 1.27M | 562K | 1.12M | 10.02M |
| Tax Payables | 0 | 22K | 39K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 327.45K | 893.51K | 2.69M | 8.65M | 11.2M |
| Total Current Liabilities | 327.45K | 893.51K | 5.26M | 14.66M | 31.98M |
| Long-term Debt | 0 | 0 | 9.22M | 22.47M | 15.32M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 3.73M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 3.73M | 0 | 0 | 0 |
| Total Non-current Liabilities | 3.73M | 3.73M | 9.22M | 23.9M | 21.78M |
| Total Liabilities | 4.05M | 4.62M | 14.47M | 38.56M | 53.76M |
| Common Stock | 129.67M | 131.53M | 259.37M | 509.81M | 513.28M |
| Retained Earnings | (2.28M) | (4.11M) | (199.59M) | (254.73M) | (372.03M) |
| Accumulated OCI | 0 | 0 | (1.02M) | (1.42M) | (888K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 127.39M | 127.42M | 72.49M | 272.61M | 167.71M |
| Total Debt | 4.16M | 32.11M | 9.78M | 25.02M | 31.8M |
| Net Debt | (1.07M) | (314.15K) | (71.74M) | (147.98M) | (18.36M) |
enGene Holdings Inc.
NASDAQ:ENGN
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.